Source: Fortune
Summary
IHH Healthcare, Asia’s largest private health group, is expanding its focus on preventive care and longevity through its new Healthspan program. CEO Prem Kumar Nair highlighted the rise in lifestyle diseases due to aging populations and increased affluence. The program includes clinical interventions and the use of GLP-1 drugs to address obesity and metabolic diseases. IHH is also investing in AI, cancer research, and community-based healthcare facilities. The company, which operates in 10 countries, reported $6 billion in 2025 revenue and is expanding into new markets like Indonesia and Vietnam.
Our Reading
The announcement sounds familiar.
IHH Healthcare is pivoting toward preventive care and longevity.
The CEO points to rising lifestyle diseases among aging, wealthier populations.
The company is investing in clinical programs, AI, and cancer research.
Healthspan is a new initiative focused on science over aesthetics.
The original observation: Asia’s aging population is reshaping healthcare demand.
Author: Evan Null
Dual-listed in Singapore and Malaysia
IHH Healthcare was incorporated in 2010 as a holding company for Malaysian sovereign wealth fund Khazanah Nasional Berhad’s healthcare investments. It was converted into a public company in 2012 and went public via a dual IPO on Bursa Malaysia and the Singapore Stock Exchange (SGX). IHH’s $2 billion IPO was the third-biggest listing globally that year, after Facebook and Felda Global Ventures Holding. IHH shares are up by more than 20% over the past 12 months.
Covid: ‘All hands on deck’
The most significant event in Prem’s tenure came with the start of the COVID-19 pandemic in Singapore. As IHH’s Singapore CEO, Prem and his team dispatched medical staff to checkpoints and foreign worker dormitories during the outbreak. The pandemic reinforced the need for public-private collaboration in health crises. IHH’s diversified presence across multiple countries has helped it navigate market volatility, with Malaysia, Singapore, and other markets supporting its performance during economic challenges.
Future of healthcare
Prem notes that the mix of specialties in Asia’s healthcare institutions is shifting. Cardiology was once the biggest specialty, but cancer is now the focus, with IHH investing in cancer testing, genomic medicine, and precision medicine. The company led a $20 million Series A funding round for Lucence, a genomic medicine firm, and invests in proton therapy machines. IHH is also expanding into AI-driven healthcare solutions, including an AI-powered nurse rostering system that has won a health innovation award from Singapore’s Ministry of Health.
Expanding into new markets
IHH is considering expansion into adjacent countries like Indonesia and Vietnam, where regulatory changes allow foreign doctors and private hospitals. Prem acknowledges that existing markets will eventually become saturated, necessitating new opportunities. Other players like Thompson and Raffles Medical have already entered Vietnam, and IHH is evaluating similar opportunities. The company is also expanding its IHH Catalyst program to North Asia, focusing on oncology, chronic disease management, and preventive care.
AI and healthcare innovation
IHH is leveraging AI to improve healthcare efficiency, including an AI-powered nurse rostering system called NurseShift.ai, which has won a health innovation award. The company is also developing AI-enabled clinical pathways that analyze patient symptoms and suggest treatment plans. Prem emphasizes that while AI can standardize care, human medical judgment remains essential. The goal is to reduce resource wastage by minimizing variations in treatment approaches across different specialists.
